Q-omics provides the consensus-scored NXPH4 profile across patient tissues and cancer cell-line models. NXPH4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, NXPH4 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, NXPH4 RNA expression shows 14,852 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRP, KIRC, and ESCA as cancer lineages where NXPH4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NXPH4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NXPH4 survival associations across molecular data types. NXPH4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NXPH4 RNA expression–survival associations across cancer types. High NXPH4 expression shows unfavorable associations in KIRP, ACC, BLCA, COAD, LIHC and UVM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for NXPH4 RNA expression.
This table summarizes NXPH4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NXPH4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NXPH4 shows higher tumor expression in KIRC, HNSC, COAD, LIHC, UCEC and BLCA. The KIRC box plot shows higher NXPH4 RNA expression in tumor versus normal tissue (log2 FC = +3.574, t-test p < 0.001).
This table shows molecular features associated with NXPH4 in patient tissues and cancer cell lines. In patient samples, NXPH4 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, NXPH4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
